Gene test could tailor chemo for pancreatic cancer patients

NCT ID NCT04683315

Recruiting now Disease control Sponsor: Medical College of Wisconsin Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a genetic test (PurIST) can help doctors choose the best chemotherapy for people with pancreatic cancer that can be surgically removed. About 84 participants will have their tumor genes analyzed from a biopsy sample, then receive a chemo plan matched to their cancer type. The goal is to see if this personalized approach leads to better tumor shrinkage before surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

Froedtert & the Medical College of Wisconsin
RECRUITING

Milwaukee, Wisconsin, 53226, United States
HonorHealth Medical Group
RECRUITING

Scottsdale, Arizona, 85258-4566, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.